Travere Therapeutics Inc. announced preliminary, unaudited financial results for the fourth quarter and full year 2025, expecting total U.S. net product sales of approximately $127 million for the quarter and $410 million for the year. The company highlighted record U.S. FILSPARI product sales, reaching about $103 million in the fourth quarter of 2025, driven by an all-time high of 908 new patient start forms. Travere ended 2025 with around $323 million in cash, cash equivalents, and marketable securities. The company also indicated it is positioned for a successful commercial launch of FILSPARI in FSGS, pending approval, and plans to restart the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112088170) on January 12, 2026, and is solely responsible for the information contained therein.